Although current SMA treatments have focused on increasing SMN levels via splice-altering drugs, the new findings suggest that modulating the activity of molecular chaperones like Hsc70-4/HspA8 could be a promising alternative or combinatorial approach. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.